Top 10 Companies in the (S)-4-tert-Butylphenyl Glycidyl Ether (CAS No. 250778-94-0) Market (2026): Market Leaders Powering Global Specialty Chemicals

MARKET INSIGHTS

The Global (S)-4-tert-Butylphenyl glycidyl ether (CAS No. 250778-94-0) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 6.4% during the forecast period.

(S)-4-tert-Butylphenyl glycidyl ether is a chiral epoxide compound derived from the reaction of (S)-glycidol with 4-tert-butylphenol. Characterized by its asymmetric oxirane ring and a sterically bulky tert-butyl substituent on the aromatic ring, this specialty chemical serves as a valuable building block in asymmetric synthesis and pharmaceutical intermediate applications. Its well-defined stereochemistry makes it particularly sought after in enantioselective reactions, where precise molecular configuration is critical to the desired biological or chemical outcome.

The market is witnessing steady expansion, driven primarily by growing demand from the pharmaceutical and fine chemicals industries, where chiral intermediates are increasingly essential for the development of optically pure active pharmaceutical ingredients (APIs). Furthermore, rising investment in asymmetric catalysis research and the broader push toward green chemistry methodologies are reinforcing demand. Key specialty chemical manufacturers and chiral reagent suppliers across North America, Europe, and Asia-Pacific continue to expand their portfolios to address these evolving requirements, positioning this niche yet strategically important compound for sustained market growth through the forecast period.

(S)-4-tert-Butylphenyl glycidyl ether (CAS No. 250778-94-0) Market – View in Detailed Research Report

---

Top 10 Companies in the (S)-4-tert-Butylphenyl Glycidyl Ether Market

10. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: Pharmaceutical intermediates, chiral glycidyl ethers, epoxy curing agents

Merck KGaA is a leading global specialty chemical company with a strong focus on pharmaceutical intermediates. Its portfolio includes high‑purity (S)-4‑tert‑butylphenyl glycidyl ether produced via proprietary asymmetric synthesis, supporting single‑enantiomer drug development. The company’s extensive R&D and integrated manufacturing facilities enable rapid scale‑up and consistent quality for large‑volume pharmaceutical production.

Sustainability & Growth Initiatives:

• Investment in green chemistry and low‑energy synthesis routes.
• ISO 9001, ISO 14001, and REACH compliant production.
• Strategic partnerships with contract manufacturing organizations to expand API supply chains.

9. Tokyo Chemical Industry Co., Ltd.

Headquarters: Tokyo, Japan
Key Offering: Chiral reagents, epoxy intermediates, polymer additives

Tokyo Chemical Industry (TCI) supplies high‑purity chiral glycidyl ethers to the pharmaceutical and fine‑chemical sectors. Leveraging advanced asymmetric synthesis technologies, TCI delivers (S)-4‑tert‑butylphenyl glycidyl ether with >98% ee, meeting stringent API specifications. The company’s global distribution network and focus on quality control ensure reliable supply for research and industrial users.

Sustainability & Growth Initiatives:

• Development of energy‑efficient catalytic processes.
• Commitment to zero‑waste manufacturing.
• Collaboration with academic institutions on green epoxide chemistry.

8. Biosynth

Headquarters: Basel, Switzerland
Key Offering: Custom synthesis, chiral intermediates, specialty chemicals

Biosynth specializes in custom synthesis of chiral building blocks, including (S)-4‑tert‑butylphenyl glycidyl ether. The company’s flexible production capacity supports small‑batch, high‑purity orders for R&D and early‑stage drug discovery, while maintaining rigorous quality assurance protocols.

Sustainability & Growth Initiatives:

• Adoption of renewable feedstocks for epoxide synthesis.
• Implementation of closed‑loop solvent recycling.
• Partnerships with biotech firms to develop novel chiral ligands.

7. Enamine Ltd.

Headquarters: Kyiv, Ukraine
Key Offering: Chiral reagents, medicinal chemistry intermediates, polymer precursors

Enamine provides high‑purity (S)-4‑tert‑butylphenyl glycidyl ether to the pharmaceutical and fine‑chemical markets. The company’s proprietary asymmetric resolution techniques enable consistent enantiomeric excess, while its agile production model supports rapid scale‑up for emerging therapeutic programs.

Sustainability & Growth Initiatives:

• Investments in catalytic asymmetric synthesis.
• Focus on reducing hazardous waste streams.
• Collaborations with academic researchers on green chemistry projects.

6. Daicel Corporation

Headquarters: Tokyo, Japan
Key Offering: Chiral reagents, specialty polymers, epoxide intermediates

Daicel’s portfolio of chiral epoxides includes (S)-4‑tert‑butylphenyl glycidyl ether, produced with high optical purity for pharmaceutical intermediates and advanced polymer applications. The company’s strong R&D capability ensures continuous improvement in synthesis efficiency and purity.

Sustainability & Growth Initiatives:

• Development of greener synthesis routes using recyclable catalysts.
• Implementation of energy‑saving manufacturing processes.
• Strategic alliances with contract manufacturers to broaden market reach.

5. Thermo Fisher Scientific (Alfa Aesar Division)

Headquarters: Boston, USA
Key Offering: Research chemicals, chiral reagents, laboratory supplies

Thermo Fisher Scientific’s Alfa Aesar division supplies high‑purity (S)-4‑tert‑butylphenyl glycidyl ether to research and industrial users worldwide. The company’s robust quality control infrastructure and global distribution network support timely delivery of small‑to‑medium‑scale orders.

Sustainability & Growth Initiatives:

• Adoption of sustainable sourcing practices.
• Reduction of single‑use plastic packaging.
• Investment in green chemistry research collaborations.

4. Synthonix Inc.

Headquarters: San Francisco, USA
Key Offering: Custom synthesis, chiral intermediates, specialty chemicals

Synthonix specializes in the synthesis of chiral building blocks, including (S)-4‑tert‑butylphenyl glycidyl ether, for pharmaceutical and fine‑chemical applications. The company’s flexible production capacity and focus on quality assurance make it a preferred partner for early‑stage drug discovery programs.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient manufacturing processes.
• Use of renewable feedstocks for epoxide production.
• Partnerships with contract manufacturing organizations for scalable production.

3. Apollo Scientific Ltd.

Headquarters: London, UK
Key Offering: Research chemicals, chiral reagents, specialty intermediates

Apollo Scientific supplies high‑purity (S)-4‑tert‑butylphenyl glycidyl ether to the pharmaceutical and fine‑chemical sectors. The company’s rigorous analytical testing ensures consistent enantiomeric excess, while its agile production model supports rapid turnaround for research‑grade orders.

Sustainability & Growth Initiatives:

• Adoption of green synthesis routes.
• Reduction of hazardous waste streams.
• Collaboration with academic researchers on chiral catalyst development.

2. Chem‑Impex International Inc.

Headquarters: New York, USA
Key Offering: Specialty chemicals, chiral intermediates, laboratory reagents

Chem‑Impex International provides (S)-4‑tert‑butylphenyl glycidyl ether to research institutions and pharmaceutical manufacturers. The company’s quality management system ensures compliance with international regulatory standards and consistent product purity.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop solvent recycling.
• Investment in energy‑saving manufacturing technologies.
• Partnerships with contract manufacturing organizations for scalable production.

1. MedKoo Biosciences Inc.

Headquarters: San Jose, USA
Key Offering: Custom synthesis, chiral reagents, pharmaceutical intermediates

MedKoo Biosciences delivers high‑purity (S)-4‑tert‑butylphenyl glycidyl ether for pharmaceutical and fine‑chemical applications. The company’s flexible production capacity and focus on quality control make it a reliable partner for early‑stage drug discovery and large‑scale manufacturing.

Sustainability & Growth Initiatives:

• Adoption of green chemistry principles in synthesis.
• Reduction of hazardous waste and energy consumption.
• Collaboration with academic institutions on chiral catalyst research.

Download FREE Sample Report: View Sample

---

Get Full Report: View Detailed Report

---

Outlook and Forecast

The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, reflecting a CAGR of 6.4% over the forecast period. Growth is driven by increasing demand for chiral intermediates in pharmaceutical development, expanding investment in asymmetric catalysis research, and a broader shift toward green chemistry. The Asia‑Pacific region is expected to capture the majority of growth due to rapid industrialization and advanced materials manufacturing, while Europe and North America will maintain steady demand driven by regulatory compliance and high‑purity requirements.

Future Trends and Opportunities

• Advances in enantioselective synthesis technologies increasing production efficiency and reducing cost.
• Expansion of chiral glycidyl ether applications in advanced polymer and liquid crystal materials, driving new end‑use markets.
• Growing focus on sustainability and compliance with global chemical regulations such as REACH and TSCA.
• Emerging collaborations between academia and industry to develop novel chiral ligands and catalysts.
• Potential for increased adoption in automotive and aerospace composite coatings, driven by demand for high‑performance, lightweight materials.